Sanofi ends development of Clostridium difficile vaccine
01 Dec 2017
Vaccine
Press Release
Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)
Sanofi ends development of
Clostridium difficile
vaccine
Paris, France - December 1, 2017
- Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III
Cdiffense
clinical trial program concluded that the probability that the study will meet its primary objective is low. Based on this, Sanofi has therefore decided to discontinue clinical development of its experimental
Clostridium difficile
vaccine, to focus on six key vaccine projects currently in development.
Cdiffense
is a trial designed to test the efficacy and safety of a candidate toxoid vaccine in a subpopulation at risk of
Clostridium difficile
infection.
Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees. In addition, investigators are notifying study volunteers of the decision to stop the program. Data from all vaccinated volunteers in this trial will continue to be analyzed for more information and shared with the scientific community.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Media Relations Contact
Laurence Bollack
Tel. : +33 (0)1 53 77 46 46
mr@sanofi.com
Investor Relations Contact
George Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.